来特莫韦预防按移植物来源的临床影响差异:一项KSGCT多中心回顾性分析
该多中心回顾性分析纳入2194例CMV血清阳性的异基因造血干细胞移植受者,其中236例接受来特莫韦预防、1958例未预防。来特莫韦组100天时临床显著CMV感染(csCMVi)显著低于未预防组(23.7% vs 58.7%,P < .001),骨髓和外周血干细胞移植受者中6个月非复发死亡率(NRM)来特莫韦组更低,但脐血移植受者NRM两组相当。
要点
- 来特莫韦预防组100天csCMVi为23.7%,未预防组为58.7%(P < .001)。
- 骨髓移植受者6个月NRM来特莫韦组5.0% vs 未预防组14.9%(P = .018)。
- 脐血移植受者NRM两组全程相当(6个月23.6% vs 24.3%,P = .92)。
核心结论
- 来特莫韦预防对NRM和csCMVi的影响应按移植物来源分别考虑。
研究设计与样本
- 多中心回顾性分析纳入2194例CMV血清阳性异基因造血干细胞移植受者,其中来特莫韦预防236例、未预防1958例。
主要发现
- 来特莫韦组100天csCMVi为23.7%,未预防组为58.7%(P < .001),骨髓、外周血干细胞和脐血移植受者分别分析时趋势一致。
- 骨髓移植受者6个月NRM来特莫韦组5.0% vs 未预防组14.9%(P = .018);外周血干细胞移植受者6个月NRM来特莫韦组14.7% vs 未预防组24.8%(P = .062)。
- 1年NRM骨髓移植受者来特莫韦组21.1% vs 未预防组30.4%(P = .67);外周血干细胞移植受者来特莫韦组21.2% vs 未预防组30.4%(P = .096)。
- 脐血移植受者NRM两组全程相当:6个月来特莫韦组23.6% vs 未预防组24.3%(P = .92),1年来特莫韦组29.3% vs 未预防组31.0%(P = .77),多因素分析证实。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Clinically significant cytomegalovirus infection (csCMVi) is frequently observed after allogeneic hematopoietic stem cell transplantation (HSCT) and prophylaxis with letermovir is commonly adopted. However, the clinical benefit of letermovir prophylaxis according to graft sources has not been sufficiently elucidated. We retrospectively analyzed 2194 recipients of HSCT who were CMV-seropositive (236 with letermovir prophylaxis and 1958 without prophylaxis against CMV). csCMVi was significantly less frequent in patients with letermovir prophylaxis than in those without (23.7% vs 58.7% at 100 days after HSCT, P < .001) and the same trend was seen when recipients of bone marrow (BM), peripheral blood stem cell (PBSC), or cord blood (CB) transplantation were separately analyzed. In recipients of BM, nonrelapse mortality (NRM) was significantly lower in the letermovir group at 6 months after HSCT (5.0% vs 14.9%, P = .018), and the same trend was observed in recipients of PBSCs (14.7% vs 24.8%, P = .062); however, there was no statistical significance at 1 year (BM, 21.1% vs 30.4%, P = .67; PBSCs, 21.2% vs 30.4%, P = .096). In contrast, NRM was comparable between recipients of CB with and without letermovir prophylaxis throughout the clinical course (6 months, 23.6% vs 24.3%, P =.92; 1 year, 29.3% vs 31.0%, P = .77), which was confirmed by multivariate analyses. In conclusion, the impact of letermovir prophylaxis on NRM and csCMVi should be separately considered according to graft sources.
引用
- Toya T, Mizuno K, Sakurai M, et al. Differential clinical impact of letermovir prophylaxis according to graft sources: a KSGCT multicenter retrospective analysis. Blood Adv. 2024. PMID: 38330190. doi:10.1182/bloodadvances.2023010735
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。